These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 17256449)

  • 1. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers.
    Avenoso A; Facciolà G; Scordo MG; Spina E
    Ther Drug Monit; 1999 Oct; 21(5):577-9. PubMed ID: 10519458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes.
    Berle JØ; Steen VM; Aamo TO; Breilid H; Zahlsen K; Spigset O
    J Clin Psychiatry; 2004 Sep; 65(9):1228-34. PubMed ID: 15367050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.
    Spina E; Santoro V; D'Arrigo C
    Clin Ther; 2008 Jul; 30(7):1206-27. PubMed ID: 18691982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.
    Caccia S
    Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator.
    Jornil J; Jensen KG; Larsen F; Linnet K
    Drug Metab Dispos; 2010 Mar; 38(3):376-85. PubMed ID: 20007670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
    J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetics and drug interactions of antidepressive agents].
    Sawada Y; Ohtani H
    Nihon Rinsho; 2001 Aug; 59(8):1539-45. PubMed ID: 11519155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.
    Chen R; Wang H; Shi J; Shen K; Hu P
    Eur J Clin Pharmacol; 2015 Jul; 71(7):835-41. PubMed ID: 25967538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
    Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
    J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
    McCune JS; Lindley C; Decker JL; Williamson KM; Meadowcroft AM; Graff D; Sawyer WT; Blough DK; Pieper JA
    J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
    Wang JS; DeVane CL
    Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
    Tushar T; Vinod T; Rajan S; Shashindran C; Adithan C
    Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):269-72. PubMed ID: 17371531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.
    McAlpine DE; Biernacka JM; Mrazek DA; O'Kane DJ; Stevens SR; Langman LJ; Courson VL; Bhagia J; Moyer TP
    Ther Drug Monit; 2011 Feb; 33(1):14-20. PubMed ID: 21099743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.